Cogent Biosciences
Develops bezuclastinib and other mutation-targeted therapies for mast-cell disease and cancer.
$34.59
After-hours close−0.08 (−0.24%)
At close$34.67(−6.52%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 117.36%Insiders 3.96%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 170.87M · Float 148.52M · 86.9% free float
Institutions13F, as of Jun 30, 2026
335 holders · 200.54M shares · 68 new positions · 207 increased · 84 reduced · 47 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 25.68M | 15.03% | +2.56M | Aug 13, 2026 |
| BlackRock, Inc. | 17.35M | 10.16% | +1.31M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 8.07M | 4.72% | +739.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 7.41M | 4.34% | +517.4K | Aug 13, 2026 |
| State Street Corp | 6.96M | 4.08% | +1.30M | Aug 7, 2026 |
| Jupiter Topco LLC | 6.62M | 3.88% | +6.62Mnew | Aug 14, 2026 |
| Fairmount Funds Management LLC | 5.50M | 3.22% | 0 | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 5.01M | 2.93% | −4.04M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 16.57M | 13G | Feb 12, 2025 ↗ |
| Fairmount Funds Management LLCincl. Fairmount Healthcare Fund II GP LLC | 8.60% | 15.36M | 13D | Mar 31, 2026 ↗ |
| BlackRock, Inc. | 6.50% | 11.37M | 13G | Jan 21, 2026 ↗ |
| Deerfield Mgmt, L.P. | 5.29% | 9.04M | 13G | May 14, 2026 ↗ |
| Vanguard Capital Management | 5.08% | 8.69M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Fairmount Funds Management LLC | director | 5.50M | 3.22% | Mar 31, 2026 |
| Andrew R. Robbins | director, officer: President and CEO | 657.5K | 0.38% | May 21, 2026 |
| John Edward Robinson | officer: Chief Scientific Officer | 140.0K | 0.08% | Dec 30, 2025 |
| Jessica Sachs | officer: Chief Medical Officer | 133.9K | 0.08% | Dec 30, 2025 |
| John L. Green | officer: Chief Financial Officer | 131.8K | 0.08% | Dec 30, 2025 |
| Evan Kearns | officer: Chief Legal Officer | 109.4K | 0.06% | Dec 30, 2025 |
| Cole Pinnow | officer: Chief Commercial Officer | 97.5K | 0.06% | Dec 19, 2025 |
5 ten-percent owners hold 2.83M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 15 people have not refiled in the last 18 months (9.15M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 31, 2026 | Fairmount Funds Management LLCdirector | Sale | 7,000,000 | $34.66 | 5,503,418 |
| Jan 22, 2026 | Fairmount Funds Management LLCdirector | Sale | 3,500,000 | $36.40 | 5,503,418 |
| Dec 26, 2025 | John Edward Robinsonofficer: Chief Scientific Officer | Sale | 90,000 | $38.74 | 140,002 |
| Dec 26, 2025 | Jessica Sachsofficer: Chief Medical Officer | Sale | 82,642 | $38.70 | 133,938 |
| Dec 26, 2025 | John L. Greenofficer: Chief Financial Officer | Sale | 77,000 | $38.68 | 131,834 |
| Dec 26, 2025 | Evan Kearnsofficer: Chief Legal Officer | Sale | 65,000 | $38.70 | 109,398 |
CongressHouse and Senate disclosures
Not reported.